Clinical Trials Unit
Stanford University School of Medicine's Center for Advanced Dermatologic Investigation is the Dermatology Department's clinical trials unit.
The Center is home to 12-15 ongoing clinical studies, investigating the safety and efficacy of new and currently available drugs and over-the-counter medications. The Center works with Stanford's own panel on medical research, leading pharmaceutical companies,and the Food and Drug Administration to safely and ethically expand the medical field's knowledge of dermatologic treatments. New studies begin regularly, and the Center continues to recruit patients with skin aging, sun damage, skin cancer (including basal cell carcinomas), psoriasis, atopic dermatitis, rosacea, and other dermatologic diseases for ongoing studies.
Skin Aging Studies
We seek to understand the human aging processes as it relates to skin on a fundamental level. To this end, our studies focus on clinical and translational research efforts ranging from: (1) the analysis of gene changes which predispose individuals to exceptionally youthful skin to (2) molecular signatures that may be biomarkers for aging skin to (3) the careful study of new candidate agents which might affect the skin aging process.
Nonmelanoma Skin Cancer
Recent advances in our understanding of basal cell skin cancer biology have enabled the development of cutting edge study drugs which combat tumor growth. We are currently home to a number of clinical trials at the forefront of potential therapy for advanced or metastatic basal cell cancer. In addition, we seek to understand the biology of basal cell skin cancers and to identify molecular predictors for treatment success.
Acne Rosecea
This is a common and frustrating chronic inflammatory condition of the face, usually affecting older individuals. The causes of this complex condition are the subject of much study. Our clinical studies seek to identify new topical or oral medications to improve the symptoms of acne rosacea.
Contact
For more information, please email dermtrials@stanford.edu
Featured Clinical Trials
TReatment for ImmUne Mediated PathopHysiology
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: High-dose methylprednisolone
- drug: Equine anti-thymocyte globulin
- drug: Prednisolone
- drug: Placebo for prednisolone
- drug: Placebo for infusions
- drug: Diphenhydramine
- drug: Methylprednisolone
Eligibility
Inclusion Criteria:
1. Patient with liver injury of ≤ 6 weeks duration resulting in an international
normalized ratio (INR) of ≥ 1.5 and < 2.0 (not corrected by vitamin K) with evidence
of hepatic encephalopathy (HE) or INR ≥ 2.0 without evidence of HE.
2. Age is greater than or equal to 1 year and less than 18 years of age.
3. Patient or their legally authorized representative(s) (LAR) must consent (and assent,
if applicable) to be in the study and must have signed and dated an approved informed
consent form which conforms to federal and institutional guidelines.
4. Females of reproductive potential should not plan on conceiving children during the
study and must agree to use a medically accepted form of contraception.
Exclusion Criteria:
1. Evidence of active infection with Hepatitis A, B, C, E or evidence of acute herpes
simplex virus (HSV) or adenovirus infection
2. Travel within the past 3 months to an area highly endemic for Hepatitis E
3. Diagnosis of hemophagocytic lymphohistiocytosis (HLH) Note: Patients with a history of
consanguinity and/or central nervous system (CNS) dysfunction that is exaggerated
compared to the degree of liver dysfunction (as judged by the site investigator) will
not be enrolled until results of rapid genetic testing are available. Turn-around time
for genetic testing results is estimated to be 72-96 hours.
4. Aplastic anemia as defined by standardized criteria [1] diagnosed prior to enrollment
5. Diagnosis of autoimmune Hepatitis (AIH)
6. Diagnosis of acute Wilson disease
7. Diagnosis of inborn error of metabolism Note: Suspicion of metabolic disease is not an
exclusion for entry into the Trial.
8. Diagnosis of acute drug or toxin-induced liver injury
9. History of recreational drug use within the past 4 weeks
10. Therapy with an immunosuppressive agent, including chemotherapy, biological therapies
or an experimental drug or device within the past 6 weeks
11. Liver injury due to ischemia
12. Liver dysfunction diagnosed more than 6 weeks prior to screening
13. History of allergy to horse dander
14. Sepsis
15. Imminent risk of death as judged by the clinical site investigator, including but not
limited to; signs of cerebral herniation at the time of enrollment and presence of
intractable arterial hypotension
16. Solid organ or stem cell transplant recipient
17. Pregnant or breast-feeding at the time of proposed study entry
18. Clinical AIDS or HIV positive
19. History of any form of malignant neoplasm and/or tumors treated within five years
prior to study entry (other than non-melanoma skin cancer or in situ cervical cancer)
or where there is current evidence of recurrent or metastatic disease
20. Received a live-virus vaccine within 4 weeks of study entry
21. Positive test result for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection
22. Psychiatric or addictive disorders that would preclude obtaining informed
consent/assent
23. Patient is unwilling or unable to adhere with study requirements and procedures
24. Currently receiving other experimental therapies
Ages Eligible for Study
1 Year - 18 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Amrita Narang, MD
312-498-5294
I'm interested
Psoriasis Clinical Trials
TReatment for ImmUne Mediated PathopHysiology
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: High-dose methylprednisolone
- drug: Equine anti-thymocyte globulin
- drug: Prednisolone
- drug: Placebo for prednisolone
- drug: Placebo for infusions
- drug: Diphenhydramine
- drug: Methylprednisolone
Eligibility
Inclusion Criteria:
1. Patient with liver injury of ≤ 6 weeks duration resulting in an international
normalized ratio (INR) of ≥ 1.5 and < 2.0 (not corrected by vitamin K) with evidence
of hepatic encephalopathy (HE) or INR ≥ 2.0 without evidence of HE.
2. Age is greater than or equal to 1 year and less than 18 years of age.
3. Patient or their legally authorized representative(s) (LAR) must consent (and assent,
if applicable) to be in the study and must have signed and dated an approved informed
consent form which conforms to federal and institutional guidelines.
4. Females of reproductive potential should not plan on conceiving children during the
study and must agree to use a medically accepted form of contraception.
Exclusion Criteria:
1. Evidence of active infection with Hepatitis A, B, C, E or evidence of acute herpes
simplex virus (HSV) or adenovirus infection
2. Travel within the past 3 months to an area highly endemic for Hepatitis E
3. Diagnosis of hemophagocytic lymphohistiocytosis (HLH) Note: Patients with a history of
consanguinity and/or central nervous system (CNS) dysfunction that is exaggerated
compared to the degree of liver dysfunction (as judged by the site investigator) will
not be enrolled until results of rapid genetic testing are available. Turn-around time
for genetic testing results is estimated to be 72-96 hours.
4. Aplastic anemia as defined by standardized criteria [1] diagnosed prior to enrollment
5. Diagnosis of autoimmune Hepatitis (AIH)
6. Diagnosis of acute Wilson disease
7. Diagnosis of inborn error of metabolism Note: Suspicion of metabolic disease is not an
exclusion for entry into the Trial.
8. Diagnosis of acute drug or toxin-induced liver injury
9. History of recreational drug use within the past 4 weeks
10. Therapy with an immunosuppressive agent, including chemotherapy, biological therapies
or an experimental drug or device within the past 6 weeks
11. Liver injury due to ischemia
12. Liver dysfunction diagnosed more than 6 weeks prior to screening
13. History of allergy to horse dander
14. Sepsis
15. Imminent risk of death as judged by the clinical site investigator, including but not
limited to; signs of cerebral herniation at the time of enrollment and presence of
intractable arterial hypotension
16. Solid organ or stem cell transplant recipient
17. Pregnant or breast-feeding at the time of proposed study entry
18. Clinical AIDS or HIV positive
19. History of any form of malignant neoplasm and/or tumors treated within five years
prior to study entry (other than non-melanoma skin cancer or in situ cervical cancer)
or where there is current evidence of recurrent or metastatic disease
20. Received a live-virus vaccine within 4 weeks of study entry
21. Positive test result for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection
22. Psychiatric or addictive disorders that would preclude obtaining informed
consent/assent
23. Patient is unwilling or unable to adhere with study requirements and procedures
24. Currently receiving other experimental therapies
Ages Eligible for Study
1 Year - 18 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Amrita Narang, MD
312-498-5294
I'm interested
Dermatology Clinical Trials
TReatment for ImmUne Mediated PathopHysiology
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: High-dose methylprednisolone
- drug: Equine anti-thymocyte globulin
- drug: Prednisolone
- drug: Placebo for prednisolone
- drug: Placebo for infusions
- drug: Diphenhydramine
- drug: Methylprednisolone
Eligibility
Inclusion Criteria:
1. Patient with liver injury of ≤ 6 weeks duration resulting in an international
normalized ratio (INR) of ≥ 1.5 and < 2.0 (not corrected by vitamin K) with evidence
of hepatic encephalopathy (HE) or INR ≥ 2.0 without evidence of HE.
2. Age is greater than or equal to 1 year and less than 18 years of age.
3. Patient or their legally authorized representative(s) (LAR) must consent (and assent,
if applicable) to be in the study and must have signed and dated an approved informed
consent form which conforms to federal and institutional guidelines.
4. Females of reproductive potential should not plan on conceiving children during the
study and must agree to use a medically accepted form of contraception.
Exclusion Criteria:
1. Evidence of active infection with Hepatitis A, B, C, E or evidence of acute herpes
simplex virus (HSV) or adenovirus infection
2. Travel within the past 3 months to an area highly endemic for Hepatitis E
3. Diagnosis of hemophagocytic lymphohistiocytosis (HLH) Note: Patients with a history of
consanguinity and/or central nervous system (CNS) dysfunction that is exaggerated
compared to the degree of liver dysfunction (as judged by the site investigator) will
not be enrolled until results of rapid genetic testing are available. Turn-around time
for genetic testing results is estimated to be 72-96 hours.
4. Aplastic anemia as defined by standardized criteria [1] diagnosed prior to enrollment
5. Diagnosis of autoimmune Hepatitis (AIH)
6. Diagnosis of acute Wilson disease
7. Diagnosis of inborn error of metabolism Note: Suspicion of metabolic disease is not an
exclusion for entry into the Trial.
8. Diagnosis of acute drug or toxin-induced liver injury
9. History of recreational drug use within the past 4 weeks
10. Therapy with an immunosuppressive agent, including chemotherapy, biological therapies
or an experimental drug or device within the past 6 weeks
11. Liver injury due to ischemia
12. Liver dysfunction diagnosed more than 6 weeks prior to screening
13. History of allergy to horse dander
14. Sepsis
15. Imminent risk of death as judged by the clinical site investigator, including but not
limited to; signs of cerebral herniation at the time of enrollment and presence of
intractable arterial hypotension
16. Solid organ or stem cell transplant recipient
17. Pregnant or breast-feeding at the time of proposed study entry
18. Clinical AIDS or HIV positive
19. History of any form of malignant neoplasm and/or tumors treated within five years
prior to study entry (other than non-melanoma skin cancer or in situ cervical cancer)
or where there is current evidence of recurrent or metastatic disease
20. Received a live-virus vaccine within 4 weeks of study entry
21. Positive test result for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection
22. Psychiatric or addictive disorders that would preclude obtaining informed
consent/assent
23. Patient is unwilling or unable to adhere with study requirements and procedures
24. Currently receiving other experimental therapies
Ages Eligible for Study
1 Year - 18 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Amrita Narang, MD
312-498-5294
I'm interested
Pediatric Dermatology Clinical Trials
TReatment for ImmUne Mediated PathopHysiology
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: High-dose methylprednisolone
- drug: Equine anti-thymocyte globulin
- drug: Prednisolone
- drug: Placebo for prednisolone
- drug: Placebo for infusions
- drug: Diphenhydramine
- drug: Methylprednisolone
Eligibility
Inclusion Criteria:
1. Patient with liver injury of ≤ 6 weeks duration resulting in an international
normalized ratio (INR) of ≥ 1.5 and < 2.0 (not corrected by vitamin K) with evidence
of hepatic encephalopathy (HE) or INR ≥ 2.0 without evidence of HE.
2. Age is greater than or equal to 1 year and less than 18 years of age.
3. Patient or their legally authorized representative(s) (LAR) must consent (and assent,
if applicable) to be in the study and must have signed and dated an approved informed
consent form which conforms to federal and institutional guidelines.
4. Females of reproductive potential should not plan on conceiving children during the
study and must agree to use a medically accepted form of contraception.
Exclusion Criteria:
1. Evidence of active infection with Hepatitis A, B, C, E or evidence of acute herpes
simplex virus (HSV) or adenovirus infection
2. Travel within the past 3 months to an area highly endemic for Hepatitis E
3. Diagnosis of hemophagocytic lymphohistiocytosis (HLH) Note: Patients with a history of
consanguinity and/or central nervous system (CNS) dysfunction that is exaggerated
compared to the degree of liver dysfunction (as judged by the site investigator) will
not be enrolled until results of rapid genetic testing are available. Turn-around time
for genetic testing results is estimated to be 72-96 hours.
4. Aplastic anemia as defined by standardized criteria [1] diagnosed prior to enrollment
5. Diagnosis of autoimmune Hepatitis (AIH)
6. Diagnosis of acute Wilson disease
7. Diagnosis of inborn error of metabolism Note: Suspicion of metabolic disease is not an
exclusion for entry into the Trial.
8. Diagnosis of acute drug or toxin-induced liver injury
9. History of recreational drug use within the past 4 weeks
10. Therapy with an immunosuppressive agent, including chemotherapy, biological therapies
or an experimental drug or device within the past 6 weeks
11. Liver injury due to ischemia
12. Liver dysfunction diagnosed more than 6 weeks prior to screening
13. History of allergy to horse dander
14. Sepsis
15. Imminent risk of death as judged by the clinical site investigator, including but not
limited to; signs of cerebral herniation at the time of enrollment and presence of
intractable arterial hypotension
16. Solid organ or stem cell transplant recipient
17. Pregnant or breast-feeding at the time of proposed study entry
18. Clinical AIDS or HIV positive
19. History of any form of malignant neoplasm and/or tumors treated within five years
prior to study entry (other than non-melanoma skin cancer or in situ cervical cancer)
or where there is current evidence of recurrent or metastatic disease
20. Received a live-virus vaccine within 4 weeks of study entry
21. Positive test result for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection
22. Psychiatric or addictive disorders that would preclude obtaining informed
consent/assent
23. Patient is unwilling or unable to adhere with study requirements and procedures
24. Currently receiving other experimental therapies
Ages Eligible for Study
1 Year - 18 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Amrita Narang, MD
312-498-5294
I'm interested
TReatment for ImmUne Mediated PathopHysiology
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: High-dose methylprednisolone
- drug: Equine anti-thymocyte globulin
- drug: Prednisolone
- drug: Placebo for prednisolone
- drug: Placebo for infusions
- drug: Diphenhydramine
- drug: Methylprednisolone
Eligibility
Inclusion Criteria:
1. Patient with liver injury of ≤ 6 weeks duration resulting in an international
normalized ratio (INR) of ≥ 1.5 and < 2.0 (not corrected by vitamin K) with evidence
of hepatic encephalopathy (HE) or INR ≥ 2.0 without evidence of HE.
2. Age is greater than or equal to 1 year and less than 18 years of age.
3. Patient or their legally authorized representative(s) (LAR) must consent (and assent,
if applicable) to be in the study and must have signed and dated an approved informed
consent form which conforms to federal and institutional guidelines.
4. Females of reproductive potential should not plan on conceiving children during the
study and must agree to use a medically accepted form of contraception.
Exclusion Criteria:
1. Evidence of active infection with Hepatitis A, B, C, E or evidence of acute herpes
simplex virus (HSV) or adenovirus infection
2. Travel within the past 3 months to an area highly endemic for Hepatitis E
3. Diagnosis of hemophagocytic lymphohistiocytosis (HLH) Note: Patients with a history of
consanguinity and/or central nervous system (CNS) dysfunction that is exaggerated
compared to the degree of liver dysfunction (as judged by the site investigator) will
not be enrolled until results of rapid genetic testing are available. Turn-around time
for genetic testing results is estimated to be 72-96 hours.
4. Aplastic anemia as defined by standardized criteria [1] diagnosed prior to enrollment
5. Diagnosis of autoimmune Hepatitis (AIH)
6. Diagnosis of acute Wilson disease
7. Diagnosis of inborn error of metabolism Note: Suspicion of metabolic disease is not an
exclusion for entry into the Trial.
8. Diagnosis of acute drug or toxin-induced liver injury
9. History of recreational drug use within the past 4 weeks
10. Therapy with an immunosuppressive agent, including chemotherapy, biological therapies
or an experimental drug or device within the past 6 weeks
11. Liver injury due to ischemia
12. Liver dysfunction diagnosed more than 6 weeks prior to screening
13. History of allergy to horse dander
14. Sepsis
15. Imminent risk of death as judged by the clinical site investigator, including but not
limited to; signs of cerebral herniation at the time of enrollment and presence of
intractable arterial hypotension
16. Solid organ or stem cell transplant recipient
17. Pregnant or breast-feeding at the time of proposed study entry
18. Clinical AIDS or HIV positive
19. History of any form of malignant neoplasm and/or tumors treated within five years
prior to study entry (other than non-melanoma skin cancer or in situ cervical cancer)
or where there is current evidence of recurrent or metastatic disease
20. Received a live-virus vaccine within 4 weeks of study entry
21. Positive test result for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection
22. Psychiatric or addictive disorders that would preclude obtaining informed
consent/assent
23. Patient is unwilling or unable to adhere with study requirements and procedures
24. Currently receiving other experimental therapies
Ages Eligible for Study
1 Year - 18 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Amrita Narang, MD
312-498-5294
I'm interested
TReatment for ImmUne Mediated PathopHysiology
TReatment for ImmUne Mediated PathopHysiology (TRIUMPH) is a multi-center, three arm, randomized, controlled trial of immunosuppressive therapy for children with acute liver failure. The study will determine if suppressing inflammatory responses with either corticosteroids or equine anti-thymocyte globulin therapy improves survival for children with this rare, life-threatening condition.
Stanford is currently accepting patients for this trial.
Stanford Investigator(s):
Intervention(s):
- drug: High-dose methylprednisolone
- drug: Equine anti-thymocyte globulin
- drug: Prednisolone
- drug: Placebo for prednisolone
- drug: Placebo for infusions
- drug: Diphenhydramine
- drug: Methylprednisolone
Eligibility
Inclusion Criteria:
1. Patient with liver injury of ≤ 6 weeks duration resulting in an international
normalized ratio (INR) of ≥ 1.5 and < 2.0 (not corrected by vitamin K) with evidence
of hepatic encephalopathy (HE) or INR ≥ 2.0 without evidence of HE.
2. Age is greater than or equal to 1 year and less than 18 years of age.
3. Patient or their legally authorized representative(s) (LAR) must consent (and assent,
if applicable) to be in the study and must have signed and dated an approved informed
consent form which conforms to federal and institutional guidelines.
4. Females of reproductive potential should not plan on conceiving children during the
study and must agree to use a medically accepted form of contraception.
Exclusion Criteria:
1. Evidence of active infection with Hepatitis A, B, C, E or evidence of acute herpes
simplex virus (HSV) or adenovirus infection
2. Travel within the past 3 months to an area highly endemic for Hepatitis E
3. Diagnosis of hemophagocytic lymphohistiocytosis (HLH) Note: Patients with a history of
consanguinity and/or central nervous system (CNS) dysfunction that is exaggerated
compared to the degree of liver dysfunction (as judged by the site investigator) will
not be enrolled until results of rapid genetic testing are available. Turn-around time
for genetic testing results is estimated to be 72-96 hours.
4. Aplastic anemia as defined by standardized criteria [1] diagnosed prior to enrollment
5. Diagnosis of autoimmune Hepatitis (AIH)
6. Diagnosis of acute Wilson disease
7. Diagnosis of inborn error of metabolism Note: Suspicion of metabolic disease is not an
exclusion for entry into the Trial.
8. Diagnosis of acute drug or toxin-induced liver injury
9. History of recreational drug use within the past 4 weeks
10. Therapy with an immunosuppressive agent, including chemotherapy, biological therapies
or an experimental drug or device within the past 6 weeks
11. Liver injury due to ischemia
12. Liver dysfunction diagnosed more than 6 weeks prior to screening
13. History of allergy to horse dander
14. Sepsis
15. Imminent risk of death as judged by the clinical site investigator, including but not
limited to; signs of cerebral herniation at the time of enrollment and presence of
intractable arterial hypotension
16. Solid organ or stem cell transplant recipient
17. Pregnant or breast-feeding at the time of proposed study entry
18. Clinical AIDS or HIV positive
19. History of any form of malignant neoplasm and/or tumors treated within five years
prior to study entry (other than non-melanoma skin cancer or in situ cervical cancer)
or where there is current evidence of recurrent or metastatic disease
20. Received a live-virus vaccine within 4 weeks of study entry
21. Positive test result for the severe acute respiratory syndrome coronavirus 2
(SARS-CoV-2) infection
22. Psychiatric or addictive disorders that would preclude obtaining informed
consent/assent
23. Patient is unwilling or unable to adhere with study requirements and procedures
24. Currently receiving other experimental therapies
Ages Eligible for Study
1 Year - 18 Years
Genders Eligible for Study
All
Now accepting new patients
Contact Information
Stanford University
School of Medicine
300 Pasteur Drive
Stanford,
CA
94305
Amrita Narang, MD
312-498-5294
I'm interested